Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
GeoVax Labs, Inc. - Common Stock
(NQ:
GOVX
)
1.170
+0.010 (+0.86%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about GeoVax Labs, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness
July 01, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Economy
GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness
July 01, 2026
Recent Federal Procurement Reinforces the Importance of Sustained Investment in Domestic Vaccine Manufacturing and Diversified Medical Countermeasures
Via
TheNewswire.com
Topics
Economy
GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant Cancers
June 17, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant Cancers
June 17, 2026
Recent Publication and Growing Industry Focus on Immune-Priming Strategies Support Continued Evaluation of Gedeptin® as a Potential Complement to Checkpoint Inhibitor Therapy
Via
TheNewswire.com
GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses
June 08, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses
June 08, 2026
Publication Highlights Potential for Intratumoral Gedeptin® Therapy to Enhance Checkpoint Inhibitor Responses and Activate Systemic Anti-Tumor Immunity
Via
TheNewswire.com
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
June 03, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
June 03, 2026
Recent Industry Activity Reinforces the Need for Manufacturing Resilience, Diversified Vaccine Supply, and Health Security Amid an Evolving Global Biothreat Landscape
Via
TheNewswire.com
GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness
June 01, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness
June 01, 2026
Largest FIFA Tournament in History Expected to Draw 6.5 Million Attendees Across North America and More Than 1.2 Million International Visitors to U.S. Host Cities Amid Growing Concerns Regarding Mpox,...
Via
TheNewswire.com
Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event
May 27, 2026
"Ebola, Marburg, Hantavirus, Mpox and Beyond: Building a Resilient Infectious Disease Preparedness Strategy” Featuring GeoVax CEO David Dodd on May 28, 2026
Via
TheNewswire.com
Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event
May 27, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Stocks to Watch: NDRA, SBFM, GOVX, HIVE, ANY Trading Actively NOW!
May 26, 2026
Via
AB Newswire
Topics
Artificial Intelligence
ENDRA Life Sciences (NASDAQ: NDRA) Beats Q1 Expectations, TAEUS® Liver Imaging Advances and Strategic Review Acceleration Fuels Investor Awareness
May 26, 2026
Via
AB Newswire
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)
May 26, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)
May 26, 2026
Company Aligns Resources With Programs Demonstrating Strong Clinical, Regulatory, and Market Momentum
Via
TheNewswire.com
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
May 20, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
May 20, 2026
Company Highlights Potential Role of MVA-Based Vaccine Technologies in Addressing Emerging Hemorrhagic Fever Threats, Including Ebola and Marburg Viruses
Via
TheNewswire.com
GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats
May 18, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats
May 18, 2026
WHO Emergency Declaration of Ebola Outbreak and Ongoing Mpox Developments Reinforce the Importance of Diversified Vaccine Supply and Scalable U.S.-Based Manufacturing Capabilities
Via
TheNewswire.com
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules
May 18, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules
May 18, 2026
ATLANTA, GA - May 18, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced that it has entered into a...
Via
TheNewswire.com
GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans
May 14, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Supply Chain
GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans
May 14, 2026
ATLANTA, GA - May 14, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer,...
Via
TheNewswire.com
Topics
Supply Chain
GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold Tumors
May 13, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold Tumors
May 13, 2026
Company Expands Strategic Immuno-Oncology Positioning Around Tumor Microenvironment Modulation, Checkpoint Enhancement, and Multi-Tumor Development Potential
Via
TheNewswire.com
GeoVax Announces a Warrant Inducement Transaction
May 07, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Announces a Warrant Inducement Transaction
May 07, 2026
ATLANTA, GA - May 7, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced its entry into a warrant...
Via
TheNewswire.com
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway
May 06, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway
May 06, 2026
Company Advances to Active Clinical Execution, Supporting Potential Accelerated Path Toward Regulatory Authorization
Via
TheNewswire.com
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit